title: Analysis of postoperative PSA changes after ultrasound-guided permanent [125I] seed implantation for the treatment of prostate cancer.
abstract: The aim of this study was to explore postoperative changes in prostate-specific antigen (PSA) levels and risk factors that influence the clinical effects of ultrasound-guided permanent [(125)I] seed implantation in the treatment of prostate cancer. From July 2009 to December 2012, 41 prostate cancer patients who underwent transrectal ultrasound-guided [(125)I] seed implantation were followed up for 3-56 months. The patients were divided into 2 groups according to their results: group A, benign rebound group, 31 cases; and group B, biochemical relapse group, 10 cases. A blood analysis of group A showed that the initial PSA rise after a nadir occurred postoperatively at 16.8 ± 1.2 months, and in 65.8% (27/41) patients the rise occurred during 15-27 weeks. For group B, the initial PSA rise after a nadir occurred postoperatively at 30.2 ± 2.1 months, and the difference in the time parameter of the initial PSA rise after the nadir was statistically significant between the 2 groups (P < 0.01). During treatment, age was shown to be a risk factor for group A (P = 0.0027, P < 0.01). Postoperative changes in PSA levels after ultrasound-guided permanent [(125)I] seed implantation contributed to the assessment of the clinical treatment effects.
authors.affiliation: Department of Ultrasound, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: X L
authors.initials: XL
authors.lastname: Bian
authors.affiliation: Department of Ultrasound, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China chengzengwang@126.com.
authors.forename: C Z
authors.initials: CZ
authors.lastname: Wang
authors.affiliation: Department of Ultrasound, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Cardiovascular Ultrasound, Henan Province People's Hospital, Zhengzhou, China.
authors.forename: Y N
authors.initials: YN
authors.lastname: Li
authors.affiliation: Department of Cardiovascular Ultrasound, Henan Province People's Hospital, Zhengzhou, China.
authors.forename: L Z
authors.initials: LZ
authors.lastname: Zhang
authors.affiliation: Department of Cardiovascular Ultrasound, Henan Province People's Hospital, Zhengzhou, China.
authors.forename: L
authors.initials: L
authors.lastname: Liu
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000235:genetics / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D005500:Follow-Up Studies; D015870:Gene Expression; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000235:genetics / Q000473:pathology; D011184:Postoperative Period; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000235:genetics / Q000473:pathology; D011877:Radionuclide Imaging; D012307:Risk Factors; D025321:Surgery, Computer-Assisted; D014463:Ultrasonography
chemical_list: D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen